Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms
Steven M. Greenberg, Francesco Bax, Susanne J. van Veluw
Nature Reviews Neurology (2025)
Closed Access | Times Cited: 3
New insights into innate immunity in Alzheimer’s disease: from APOE protective variants to therapies
Yun Chen, David M. Holtzman
Trends in Immunology (2024)
Open Access | Times Cited: 5
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
Michael T. Heneka, David Morgan, Frank Jessen
The Lancet (2024) Vol. 404, Iss. 10468, pp. 2198-2208
Closed Access | Times Cited: 5


Archives of Pharmacy & Pharmacology Research (2025) Vol. 4, Iss. 4
Open Access
Challenges of Anti-Amyloid Immunotherapy for the Treatment of Alzheimer’s Disease
Gustavo Alves Andrade dos Santos
Archives of Pharmacy & Pharmacology Research (2025) Vol. 4, Iss. 4
Open Access
Anti-Amyloid Therapies for Alzheimer’s Disease and Amyloid-Related Imaging Abnormalities: Implications for the Emergency Medicine Clinician
Megan A. Rech, Christopher R. Carpenter, Neelum T. Aggarwal, et al.
Annals of Emergency Medicine (2025)
Closed Access
Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist
So Yeong Jeong, Chong Hyun Suh, Jae‐Sung Lim, et al.
Journal of the Korean Society of Radiology (2025) Vol. 86, Iss. 1, pp. 17-17
Open Access
Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus
Robert Perneczky, David Darby, Giovanni B. Frisoni, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100096-100096
Open Access
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics
Nicolas Villain, Vincent Planche, Matthieu Lilamand, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100094-100094
Open Access
Anti‐amyloid treatments: Why we think they are worth it
Suzanne E. Schindler, Erik S. Musiek, John C. Morris
Alzheimer s & Dementia Translational Research & Clinical Interventions (2025) Vol. 11, Iss. 1
Open Access
Availability of modern diagnostics and treatment of Alzheimer’s disease. Disease-modifying therapy

Medical Technologies Assessment and Choice (2025), Iss. 1, pp. 11-11
Open Access
Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy
So Yeong Jeong, Chong Hyun Suh, Jae‐Sung Lim, et al.
Neurology (2025) Vol. 104, Iss. 8
Closed Access
Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators
F. Jessen, Milica G. Kramberger, Davide Angioni, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Open Access | Times Cited: 4
Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early Alzheimer Disease
Stephen Salloway, Jakub Wojtowicz, Nicola Voyle, et al.
JAMA Neurology (2024) Vol. 82, Iss. 1, pp. 19-19
Open Access | Times Cited: 4
Central role of brain regulatory T cells in the inflammatory cascade in Alzheimer’s disease
Germán Plascencia‐Villa, Rudolph J. Castellani, George Perry
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 32
Closed Access | Times Cited: 2
Use of anti-amyloid therapies for Alzheimer’s disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology
Breno José Alencar Pires Barbosa, Elisa de Paula França Resende, Raphael Machado Castilhos, et al.
Dementia & Neuropsychologia (2024) Vol. 18
Open Access | Times Cited: 1
Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Lecanemab in Alzheimer’s disease: a profile of its use
Hannah A. Blair
Drugs & Therapy Perspectives (2024) Vol. 40, Iss. 10, pp. 393-400
Closed Access | Times Cited: 1
Dengzhan Shengmai Capsule Ameliorates Cognitive Impairment via Inhibiting ER stress in APP/PS1 Mice
Huihan Ma, Jiayi Zheng, Yuhui Qiu, et al.
Journal of Ethnopharmacology (2024) Vol. 338, pp. 119016-119016
Closed Access | Times Cited: 1
Penetratin and Mannose-Functionalized Cannabidiol Lipid Nanoparticles Encapsulating the BDNF Gene Reduce Amyloid-Induced Inflammation
Bivek Chaulagain, Jagdish Singh
Molecular Pharmaceutics (2024) Vol. 22, Iss. 1, pp. 154-167
Closed Access | Times Cited: 1
Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association
Steven M. Greenberg, Hugo J. Aparicio, Karen L. Furie, et al.
Stroke (2024)
Closed Access | Times Cited: 1
Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemab
Sung-Mi Ji, Michael Rosenbloom
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
A shorter linker in the bispecific antibody RmAb158-scFv8D3 improves TfR-mediated blood-brain barrier transcytosis in vitro
Inga Petersen, Jamie I. Morrison, Alex Petrovic, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease
Xiaoming Qi, Damir Nizamutdinov, Sheng‐Han Yi, et al.
Biomedicines (2024) Vol. 12, Iss. 11, pp. 2636-2636
Open Access
Alzheimer’s Disease Diagnosis and Management in the Age of Amyloid Monoclonal Antibodies
Chadwick M. Hales
Medical Clinics of North America (2024) Vol. 109, Iss. 2, pp. 463-483
Closed Access
Page 1 - Next Page

Scroll to top